Xue Chen,Suixin Deng,Wenchao Wang,Stefania Castiglione,Zilei Duan,Lei Luo,Francesca Cianci,Xiaoxue Zhang,Jianglei Xu,Hao Li,Jizong Zhao,Peter Muiruri Kamau,Zhiye Zhang,James Mwangi,Jiali Li,Yousheng Shu,Xintian Hu,Michele Mazzanti,Ren Lai

Abstract:As a prime mover in Alzheimer's disease (AD), microglial activation requires membrane translocation, integration, and activation of the metamorphic protein chloride intracellular channel 1 (CLIC1), which is primarily cytoplasmic under physiological conditions. However, the formation and activation mechanisms of functional CLIC1 are unknown. Here, we found that the human antimicrobial peptide (AMP) LL-37 promoted CLIC1 membrane translocation and integration. It also activates CLIC1 to cause microglial hyperactivation, neuroinflammation, and excitotoxicity. In mouse and monkey models, LL-37 caused significant pathological phenotypes linked to AD, including elevated amyloid-beta, increased neurofibrillary tangles, enhanced neuronal death and brain atrophy, enlargement of lateral ventricles, and impairment of synaptic plasticity and cognition, while Clic1 knockout and blockade of LL-37-CLIC1 interactions inhibited these phenotypes. Given AD's association with infection and that overloading AMP may exacerbate AD, this study suggests that LL-37, which is up-regulated upon infection, may be a driving force behind AD by acting as an endogenous agonist of CLIC1.

Correction to: Human antimicrobial peptide LL-37 contributes to Alzheimer's disease progression

Correction To: Human Antimicrobial Peptide LL-37 Contributes to Alzheimer’s Disease Progression

Corrigendum for “A Novel Kinase Subverts Aluminium Resistance by Boosting Ornithine Decarboxylase‐dependent Putrescine Biosynthesis”

Corrigendum: Alternative Splicing: a New Cause and Potential Therapeutic Target in Autoimmune Disease.

Correction: Investigation of plasma metabolomics and neurotransmitter dysfunction in the process of Alzheimer’s disease rat induced by amyloid beta 25-35

Correction: Investigation of plasma metabolomics and neurotransmitter dysfunction in the process of Alzheimer's disease rat induced by amyloid beta 25-35.

Correction: Up-regulation of Myelin-Associated Glycoprotein is Associated with the Ameliorating Effect of Omega-3 Polyunsaturated Fatty Acids on Alzheimer's Disease Progression in APP-PS1 Transgenic Mice.

Author Correction: Soluble TREM2 ameliorates pathological phenotypes by modulating microglial functions in an Alzheimer’s disease model

Inhibition of miR-331-3p and miR-9-5p ameliorates Alzheimer's disease by enhancing autophagy: Erratum

Correction to: Inhibition of Dectin-1 Ameliorates Neuroinflammation by Regulating Microglia/Macrophage Phenotype After Intracerebral Hemorrhage in Mice

Corrigendum: Microglia Mediate the Occurrence and Development of Alzheimer's Disease Through Ligand-Receptor Axis Communication

Author Correction: C/EBPβ Regulates Delta-Secretase Expression and Mediates Pathogenesis in Mouse Models of Alzheimer’s Disease

Correction: Cell Therapy: A Safe and Efficacious Therapeutic Treatment for Alzheimer's Disease in APP+PS1 Mice.

Author Correction: Single-cell transcriptomic analysis of Alzheimer’s disease

Correction: Musumeci et al. Intranasal Administration of a TRAIL Neutralizing Monoclonal Antibody Adsorbed in PLGA Nanoparticles and NLC Nanosystems: An In Vivo Study on a Mouse Model of Alzheimer's Disease. Biomedicines 2022, 10, 985

Author correction to ‘A nanocleaner specifically penetrates the blood‒brain barrier at lesions to clean toxic proteins and regulate inflammation in Alzheimer’s disease’ [Acta Pharmaceutica Sinica B 12 (2021) 4032‒4044]

Correction: Protective Effects of Dietary Supplementation with a Combination of Nutrients in a Transgenic Mouse Model of Alzheimer's Disease

Author Correction: Partial inhibition of mitochondrial complex I ameliorates Alzheimer's disease pathology and cognition in APP/PS1 female mice

Corrigendum: Systems Pharmacology Approach to Investigate the Mechanism of Kai-Xin-San in Alzheimer’s Disease

Author Correction: Tau-targeting antisense oligonucleotide MAPT Rx in mild Alzheimer's disease: a phase 1b, randomized, placebo-controlled trial

Author Correction: Microglia-mediated T cell infiltration drives neurodegeneration in tauopathy